Defibrotide in the treatment of hepatic veno-occlusive disease

Alessandro Fulgenzi, Maria Elena Ferrero Department of Biomedical Sciences for Health, University of Milan, Milan, Italy Abstract: Hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), represents the most frequent complication in patients in ear...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fulgenzi A, Ferrero ME
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	hepatic veno-occlusive disease hematopoietic stem-cell transplantation defibrotide Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/a08e34e221e440de9aabc1ec54fbe3b9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a08e34e221e440de9aabc1ec54fbe3b9
record_format	dspace
spelling	oai:doaj.org-article:a08e34e221e440de9aabc1ec54fbe3b92021-12-02T11:29:26ZDefibrotide in the treatment of hepatic veno-occlusive disease1179-1535https://doaj.org/article/a08e34e221e440de9aabc1ec54fbe3b92016-10-01T00:00:00Zhttps://www.dovepress.com/defibrotide-in-the-treatment-of-hepatic-veno-occlusive-disease-peer-reviewed-article-HMERhttps://doaj.org/toc/1179-1535Alessandro Fulgenzi, Maria Elena Ferrero Department of Biomedical Sciences for Health, University of Milan, Milan, Italy Abstract: Hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), represents the most frequent complication in patients in early phase following hematopoietic stem-cell transplantation (HSCT). In its severe form, VOD/SOS can be associated with multiorgan failure and with a mortality rate >80% by day +100. Defibrotide (DF) (a mixture of 90% single-stranded phosphodiester oligonucleotides and 10% double-stranded phosphodiester oligonucleotides derived from controlled depolarization of porcine intestinal mucosal DNA) has been proposed for the treatment of SOS due to its ability to restore thrombo-fibrinolytic balance and protect endothelial cells. The present review highlights why the mechanisms of action of DF allow its successful use in the prevention and treatment of SOS following HSCT. Keywords: hepatic veno-occlusive disease, hematopoietic stem-cell transplantation, defibrotideFulgenzi AFerrero MEDove Medical Pressarticlehepatic veno-occlusive diseasehematopoietic stem-cell transplantationdefibrotideDiseases of the digestive system. GastroenterologyRC799-869ENHepatic Medicine: Evidence and Research, Vol Volume 8, Pp 105-113 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	hepatic veno-occlusive disease hematopoietic stem-cell transplantation defibrotide Diseases of the digestive system. Gastroenterology RC799-869
spellingShingle	hepatic veno-occlusive disease hematopoietic stem-cell transplantation defibrotide Diseases of the digestive system. Gastroenterology RC799-869 Fulgenzi A Ferrero ME Defibrotide in the treatment of hepatic veno-occlusive disease
description	Alessandro Fulgenzi, Maria Elena Ferrero Department of Biomedical Sciences for Health, University of Milan, Milan, Italy Abstract: Hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), represents the most frequent complication in patients in early phase following hematopoietic stem-cell transplantation (HSCT). In its severe form, VOD/SOS can be associated with multiorgan failure and with a mortality rate >80% by day +100. Defibrotide (DF) (a mixture of 90% single-stranded phosphodiester oligonucleotides and 10% double-stranded phosphodiester oligonucleotides derived from controlled depolarization of porcine intestinal mucosal DNA) has been proposed for the treatment of SOS due to its ability to restore thrombo-fibrinolytic balance and protect endothelial cells. The present review highlights why the mechanisms of action of DF allow its successful use in the prevention and treatment of SOS following HSCT. Keywords: hepatic veno-occlusive disease, hematopoietic stem-cell transplantation, defibrotide
format	article
author	Fulgenzi A Ferrero ME
author_facet	Fulgenzi A Ferrero ME
author_sort	Fulgenzi A
title	Defibrotide in the treatment of hepatic veno-occlusive disease
title_short	Defibrotide in the treatment of hepatic veno-occlusive disease
title_full	Defibrotide in the treatment of hepatic veno-occlusive disease
title_fullStr	Defibrotide in the treatment of hepatic veno-occlusive disease
title_full_unstemmed	Defibrotide in the treatment of hepatic veno-occlusive disease
title_sort	defibrotide in the treatment of hepatic veno-occlusive disease
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/a08e34e221e440de9aabc1ec54fbe3b9
work_keys_str_mv	AT fulgenzia defibrotideinthetreatmentofhepaticvenoocclusivedisease AT ferrerome defibrotideinthetreatmentofhepaticvenoocclusivedisease
_version_	1718395896410931200

Defibrotide in the treatment of hepatic veno-occlusive disease

Ejemplares similares